StockData
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc. (FHTX) stock

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30
$1.83+0.04 (+2.23%)

Close on Nov 17, 2026Market cap $108.68MP/E –Yield –

Foghorn Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Foghorn Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $36.74M, up 52.0% year over year. For fiscal 2025 it was $30.91M, up 36.8% from the year before. The highest annual figure on record is $34.16M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$30.91M+36.8%
FY2024Dec 31, 2024$22.60M-33.8%
FY2023Dec 31, 2023$34.16M+77.6%
FY2022Dec 31, 2022$19.23M+1357.8%
FY2021Dec 31, 2021$1.32M+206.7%
FY2020Dec 31, 2020$430.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.07M+112.7%
Q1 FY2026Mar 31, 2026$3.27M-45.1%
Q4 FY2025Dec 31, 2025$9.25M+223.8%
Q3 FY2025Sep 30, 2025$8.15M+4.4%
Q2 FY2025Jun 30, 2025$7.56M+9.7%
Q1 FY2025Mar 31, 2025$5.95M+17.9%
Q4 FY2024Dec 31, 2024$2.86M-50.5%
Q3 FY2024Sep 30, 2024$7.81M-55.3%
Q2 FY2024Jun 30, 2024$6.89M+23.0%
Q1 FY2024Mar 31, 2024$5.05M-4.9%
Q4 FY2023Dec 31, 2023$5.77M+37.9%
Q3 FY2023Sep 30, 2023$17.48M+163.5%
Q2 FY2023Jun 30, 2023$5.60M+24.7%
Q1 FY2023Mar 31, 2023$5.31M+35.4%
Q4 FY2022Dec 31, 2022$4.18M+486.8%
Q3 FY2022Sep 30, 2022$6.63M+16080.5%
Q2 FY2022Jun 30, 2022$4.49M+1509.3%
Q1 FY2022Mar 31, 2022$3.92M+1270.6%
Q4 FY2021Dec 31, 2021$713.00K+184.1%
Q3 FY2021Sep 30, 2021$41.00K-77.1%
Q2 FY2021Jun 30, 2021$279.00K–
Q1 FY2021Mar 31, 2021$286.00K–
Q4 FY2020Dec 31, 2020$251.00K–
Q3 FY2020Sep 30, 2020$179.00K–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–

More Foghorn Therapeutics figures

See a number that looks wrong?